Welcome to our dedicated page for Pavmed SEC filings (Ticker: PAVMZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PAVmed Inc. (PAVM, PAVMZ) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures associated with its common stock and Series Z warrants. These filings offer detailed information on financial performance, capital structure, subsidiary activities, and material events that affect holders of PAVM and PAVMZ.
Recent Form 8-K filings referenced in public data include disclosures about business update press releases, quarterly financial results, and Nasdaq listing matters. For example, one 8-K describes a Nasdaq notification granting PAVmed additional time to regain compliance with the minimum bid price requirement, while another outlines the company’s announcement of financial results and a related business update. A separate 8-K details a financing transaction at Veris Health Inc., PAVmed’s majority-owned digital health subsidiary, involving the sale of Veris common stock and warrants to support development of an implantable physiological monitor.
Filings related to Lucid Diagnostics Inc., PAVmed’s diagnostics subsidiary, also appear in PAVmed’s disclosures when they represent material events for the parent company. One such 8-K describes an underwritten public offering of Lucid Diagnostics common stock under an existing shelf registration statement, with proceeds intended for working capital and general corporate purposes.
On Stock Titan, these SEC documents are supplemented by AI-powered summaries that highlight key points, such as the nature of a financing, the implications of a Nasdaq notice, or the relationship between PAVmed and its subsidiaries. Real-time updates from EDGAR help ensure that new 8-Ks, 10-Qs, 10-Ks, and other forms are surfaced quickly, while Form 4 and related insider transaction filings can be used to review equity activity by officers, directors, or significant holders.
By using this page, investors and researchers can review the underlying regulatory text while relying on AI-generated explanations to interpret complex sections, compare periods, and understand how specific filings relate to PAVmed’s medical device, diagnostics, and digital health operations and to the PAVMZ warrants.
PAVmed Inc. disclosed that its subsidiary, Lucid Diagnostics, completed an underwritten public offering of 28,750,000 shares of Lucid Diagnostics common stock at $1.00 per share, including full exercise of a 3,750,000-share underwriter option. After underwriting discounts and estimated offering expenses, the transaction is expected to generate approximately $26.9 million in net proceeds. Lucid Diagnostics intends to use the proceeds for working capital and general corporate purposes.
The filing is a straightforward capital raise by a subsidiary rather than PAVmed directly and provides a liquidity infusion for Lucid Diagnostics to support operations or near-term needs. No additional financial results, changes in ownership percentages, or specific allocations of the proceeds were disclosed in the text provided.
PAVmed Inc.'s Schedule 13G shows that Sargent Investment Group, LLC reports beneficial ownership of 1,006,300 common shares, representing 5.79% of the class. The filing identifies Sargent as an investment adviser organized in Maryland and indicates the position is held in the ordinary course of business as a passive holding under the Schedule 13G rules.
The filing discloses that Sargent does not hold sole voting power over the shares while it does report power to dispose of or direct disposition for the full amount. The statement also notes that other persons may have rights to dividends or sale proceeds, implying the economic interests are held on behalf of others rather than reflecting a controlling stake.
PAVmed Inc. furnished a Form 8-K dated August 14, 2025 reporting that it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and providing a business update. The press release is attached as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The company states the furnished information shall not be deemed "filed" under the Exchange Act nor incorporated by reference except as expressly stated. The report is signed by Dennis McGrath, President and Chief Financial Officer.